In January 2026, the Cambridge-based drug discovery company OutSee completed its oversubscribed £2.5 million ($3.2M) seed funding round. The investment was led by Ahren Innovation Capital, with participation from Kadmos Capital, Panacea, and Empirical Ventures.
The company is led by CEO and Founder Dr. Julian Gough. OutSee is pioneering a “genomics-first” approach to medicine through its proprietary platform, Nomaly, which uses AI-powered predictive modeling to identify therapeutic targets directly from fundamental molecular biology.
Traditional drug discovery often relies on large, historical datasets that can be noisy or incomplete. OutSee addresses this by predicting disease phenotypes from a single genome, allowing for discovery in complex genetics where traditional methods fail. This high-fidelity approach to biological data mirrors the shift toward predictive diagnostics, where the goal is to identify risks at the molecular level before they manifest clinically.
Alongside the funding, OutSee announced a strategic partnership with o2h discovery to progress its lead drug target candidate. The collaboration leverages o2h’s InflexionTx model to accelerate proof-of-concept studies, moving OutSee from a pure tech validation phase to active therapeutic value generation. Similar to how AI observability scales enterprise infrastructure, Nomaly provides a continuous feedback loop that turns raw genomic data into actionable drug pipelines.
Market Signal
- Ab Initio Target Discovery: OutSee’s ability to predict disease ab initio (from the beginning) is a major technological moat. It enables the company to unlock value from “small data” sets that traditional pharmaceutical pipelines typically overlook.
- The Co-Discovery Alpha: The partnership with o2h discovery validates a trend where biotech startups are bypassing traditional CRO relationships in favor of “integrated discovery” models. This shares risk and accelerates the transition from computer code to clinical assets.
- Founder-Market Fit: Dr. Julian Gough’s background in computational biology is a critical trust anchor. Investors are increasingly betting on founders who can bridge the gap between “dry lab” AI and “wet lab” validation, as seen in the oversubscription of this round.
Key Details
- Company: OutSee
- Funding: £2.5M Seed (Completed)
- Headquarters: Cambridge, UK
- Lead Investor: Ahren Innovation Capital
- CEO: Dr. Julian Gough
- Use Case: AI-powered target identification, precision medicine, and predictive genomics
